Edesa Biotech (EDSA) Total Debt (2021 - 2022)
Edesa Biotech (EDSA) posted Total Debt of $43662.0 for Q3 2022, down 7.5% sequentially from $47202.0 in Q3 2021, and down 7.5% YoY from $47202.0 in Q3 2021.
Edesa Biotech (EDSA) Total Debt (2021 - 2022) Analysis & Trends
Edesa Biotech has reported Total Debt for 2 years, with the latest figure at $43662.0 in Q3 2022.
- Quarterly Total Debt fell 7.5% year-over-year to $43662.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $43662.0 (down 7.5% YoY) and the FY2022 annual result came in at $43662.0, down 7.5% from the prior year.
- Total Debt declined to $43662.0 in Q3 2022 per EDSA's latest filing, from $47202.0 in the prior quarter.
- Over five years, Total Debt peaked at $47202.0 in Q3 2021 and troughed at $43662.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.34 Bn |
| 10 | Edesa Biotech | 40.83 Mn | 40.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 43,662.00 |
| Sep 30, 2021 | 47,202.00 |